



Characteristics of Baculovirus-Expressed rClC-1

by David St.John Astill

Thesis submitted to The Department of Physiology, Faculty of Science, The University of Adelaide as partial fulfilment of the requirements for award of the degree of Doctor of Philosophy.

Work performed in the laboratories of The Department of Physiology, The University of Adelaide and School of Pharmacy and Medical Sciences, University of South Australia.

January 1996

Awarded 1996

Contents

LIST OF FIGURES AND TABLES	ix
SUMMARY	xi
DECLARATION.....	xiii
ACKNOWLEDGMENTS.....	xv
ABBREVIATIONS	xvii
I GENERAL INTRODUCTION.....	1
I.1 SKELETAL MUSCLE CHLORIDE CONDUCTANCE.....	2
I.1.1 Whole-cell studies.....	4
I.1.2 Single channel studies.....	6
I.2 TORPEDO ELECTROPLAQUE.....	9
I.3 CLC-1.....	12
I.4 PROJECT AIMS.....	13
II PROTEIN EXPRESSION	15
II.1 INTRODUCTION.....	15
II.1.1 Baculovirus expression vectors.....	15
II.1.2 Sf insect cell lines.....	17
II.1.3 Baculovirus expressed channels.....	19
II.2 MATERIALS AND METHODS	20
II.2.1 <i>Clc-1</i> cDNA.....	20
II.2.2 Bacterial cultivation.....	20
II.2.3 Chemicals and reagents.....	20
II.2.4 Enzymes.....	21
II.2.5 Oligodeoxynucleotides	21
II.2.6 Bacterial strains and cloning vectors	22
II.2.7 Bacterial transformation.....	23
II.2.8 Plasmid isolation.....	23
II.2.9 Analysis and manipulation of DNA.....	24
II.2.9.1 DNA quantitation.....	24
II.2.9.2 Restriction endonuclease digestion.....	24
II.2.9.3 Restriction of PCR products.....	24
II.2.9.4 Analytical and preparative separation of restriction fragments.....	24
II.2.9.5 Calculation of restriction fragment size.....	25
II.2.9.6 DNA sequencing	25
II.2.9.7 End filling.....	26
II.2.9.8 DNA ligation.....	26
II.2.10 Construction of Transfer Vectors.....	27
II.2.10.1 Complete cDNA (pDA1bvr and pDA2bvr).....	27
II.2.10.2 modified cDNA (pDA5bvr and pDA6bvr).....	28
II.2.11 Cell Culture.....	30
II.2.11.1 Cell lines.....	30
II.2.11.2 Maintenance of Cell Lines.....	30
II.2.12 Recombinant virus production and amplification	31
II.2.12.1 Cell seeding densities	31
II.2.12.2 Infection of Cells.....	32
II.2.12.3 Co-transformation.....	32
II.2.12.4 Plaque assays.....	33
II.2.12.5 Isolation of recombinant virus clones.....	34
II.2.12.6 Virus amplification.....	34
II.2.12.7 Confirmation of Recombinant Virus Clones by PCR.....	35
II.2.13 Protein Expression.....	36
II.2.13.1 Polyacrylamide gel electrophoresis	36
II.2.13.2 Expression screening	36

II.2.13.3 Determination of expression time course.....	37
II.3 RESULTS.....	37
II.3.1 Construction of Transfer Vectors.....	37
II.3.1.1 Complete cDNA (pDA1bvr and pDA2bvr).....	37
II.3.1.1.1 Subcloning.....	37
II.3.1.1.2 DNA sequencing.....	38
II.3.1.2 modified cDNA (pDA5bvr and pDA6bvr).....	39
II.3.1.2.1 Recombinant PCR.....	39
II.3.1.2.2 DNA sequencing.....	40
II.3.1.2.3 Recombinant transfer vectors.....	40
II.3.2 Recombinant virus production.....	41
II.3.2.1 Co-transformations.....	41
II.3.2.2 Selection and confirmation of recombinant clones.....	41
II.3.3 Virus amplification and protein expression.....	42
II.3.3.1 Virus amplification.....	42
II.3.3.2 Expression time course.....	42
II.3.3.3 Expression time course.....	43
II.4 DISCUSSION.....	44
II.4.1 <i>Clc-1</i> cDNA.....	44
II.4.2 Construction of expression vectors.....	45
II.4.2.1 Transfer vectors.....	45
II.4.2.2 Expression vectors.....	46
II.4.2.3 Protein expression.....	46
II.4.2.3.1 Level of expression.....	46
II.4.2.3.2 Protein size.....	47
II.4.2.3.3 Expression time course.....	49
II.4.3 Conclusions.....	50
III ANTIBODY PRODUCTION.....	51
III.1 INTRODUCTION.....	51
III.1.1 Approach to anti-Clc-1 antibody production.....	53
III.2 MATERIALS AND METHODS.....	53
III.2.1 Synthetic oligopeptides.....	53
III.2.2 Chemicals, reagents and media.....	54
III.2.3 Peptide conjugation procedures.....	54
III.2.3.1 Conjugation efficiency.....	54
III.2.3.2 Conjugation to horseradish peroxidase.....	55
III.2.3.3 Conjugation to bovine serum albumin and bovine γ globulin.....	55
II.2.3.3.1 In solution.....	55
II.2.3.3.2 Solid phase.....	56
III.2.4 Enzyme-linked immunosorbent assay (ELISA).....	56
III.2.5 Dot blots.....	58
III.2.6 Inoculation protocols and serum screening.....	59
III.2.6.1 Approach 1.....	60
III.2.6.1.1 Inoculation protocol.....	60
III.2.6.1.2 Serum screening.....	60
III.2.6.2 Approach 2.....	60
III.2.6.2.1 Inoculation protocol.....	60
III.2.6.2.2 Serum screening.....	61
III.2.6.3 Approach 3.....	62
III.2.6.3.1 Inoculation protocol.....	62
III.2.6.3.2 Serum screening.....	62
III.3 RESULTS.....	62
III.3.1 Approach 1.....	62
III.3.2 Approach 2.....	63
III.3.3 Approach 3.....	65
III.4 DISCUSSION.....	66
III.4.1 Approach 1.....	66
III.4.2 Approach 2.....	66
III.4.3 Approach 3.....	67
III.4.4 General comments.....	67
III.4.4.1 Future directions.....	69

IV BIOPHYSICS.....	71
IV.1 INTRODUCTION	71
IV.1.1 CIC-1	71
IV.1.2 Other CIC family members.....	74
IV.2 MATERIALS AND METHODS	77
IV.2.1 Chemicals and Reagents.....	77
IV.2.2 Patch-clamping	77
IV.2.2.1 Cells.....	77
IV.2.2.2 Solutions	77
IV.2.2.3 Pipettes.....	78
IV.2.2.4 Apparatus and establishment of whole-cell configuration	78
IV.2.2.5 Data collection and analysis.....	79
IV.2.2.6 Voltage protocols.....	79
IV.2.2.7 Analysis	79
IV.3 RESULTS	80
IV.3.1 Cell-attached	80
IV.3.2 Whole-cell	80
IV.3.2.1 BVDA2.1 (negative control virus) and uninfected cells	80
IV.3.2.2 BVDA6.3 infected	81
IV.3.2.3 Kinetics.....	82
IV.3.2.3.1 Effect of voltage.....	82
IV.3.2.3.2 Effect of time.....	83
IV.3.2.4 Foreign anions	85
IV.4 DISCUSSION	85
IV.4.1 Negative control cells.....	85
IV.4.2 CIC-1-expressing cells.....	86
IV.4.2.1 Kinetics.....	86
IV.4.3 Conclusions	91
V PHARMACOLOGY	93
V.1 INTRODUCTION.....	93
V.1.1 Chloride channel blockers	93
V.1.2 Mammalian chloride channels	94
V.1.2.1 Epithelia	94
V.1.2.2 Skeletal muscle.....	96
V.1.3 Concluding remarks.....	99
V.2 MATERIALS AND METHODS.....	100
V.2.1 Chemicals and reagents	100
V.2.1.1 Blockers	100
V.2.2 Patch-clamping	100
V.2.2.1 Dose response.....	100
V.3 RESULTS	101
V.3.1 Anthracene-9-carboxylate.....	101
V.3.2 Perrhenate	102
V.3.3 2-(4-chlorophenoxy)-propionate.....	103
V.3.3.1 Racemate	103
V.3.3.2 Enantiomers.....	105
V.3.3.2.1 S(-).....	105
V.3.3.2.2 R(+).....	106
V.3.4 Indanyloxyacetate 94/95.....	107
V.3.5 Zinc.....	108
V.3.6 Preliminary results with other compounds.....	108
V.3.6.1 2-(3-trifluoromethylanilino)-nicotinic acid	108
V.3.6.2 2,4-dichlorophenoxyacetate	109
V.3.6.3 diphenylamine-2-carboxylate	109
V.3.6.4 5-nitro-2-(3-phenylpropylamino) benzoate	110
V.4 DISCUSSION.....	110
V.4.1 Potency	110
V.4.2 Possible modi operandi.....	113
V.4.2.1 Group 1	113
V.4.2.2 Group 2	117

V.4.2.3 Group 3	119
V.4.3 Blocker structure vs effect	123
V.4.4 Concluding remarks/ future directions	123
VI MUTAGENESIS	125
VI.1 INTRODUCTION	125
VI.1.1 CIC-1 Mutations	125
VI.1.2 Mutagenesis of CIC-0 and CIC-2	127
VI.2 AIM/ APPROACH	128
VI.3 MATERIALS AND METHODS	129
VI.3.1 Chemicals and solutions	129
VI.3.2 Molecular biology	129
VI.3.2.1 Site-directed mutagenesis	129
VI.3.3 Virus Production	130
VI.3.4 Electrophysiology	130
VI.3.5 Pharmacology	131
VI.3.5.1 Blockers	131
VI.3.5.2 pKa of Zn ⁺⁺ block	131
VI.4 RESULTS	132
VI.4.1 Mutagenesis	132
VI.4.2 Virus production	132
VI.4.3 Protein expression	132
VI.4.4 Electrophysiology	132
VI.4.4.1 Kinetics	132
VI.4.5 Selectivity	134
VI.5 PHARMACOLOGY	134
VI.5.1 Anthracene-9-carboxylate	134
VI.5.2 2-(4-chlorophenoxy)propionate	134
VI.5.3 Perrhenate	135
VI.5.4 Zinc	135
VI.5.5 pKa of Zn ⁺⁺ interaction	135
VI.6 DISCUSSION	136
VI.7 FUTURE DIRECTIONS	138
VII GENERAL DISCUSSION	139
VII.1 BACULOVIRUS SF CELL SYSTEM	139
VII.2 CLC-1 CHARACTERISTICS	139
VII.3 PHARMACOLOGY	140
VII.4 FUTURE DIRECTIONS	141
VIII APPENDICES	145
APPENDIX A	145
APPENDIX B	151
APPENDIX C	155
APPENDIX D	157
BIBLIOGRAPHY	159

Summary

The baculovirus/ Sf cell system was established and used to express rat skeletal muscle chloride channel CIC-1. Modified *clc-1* reading frames were produced and the mutant proteins encoded thereby successfully expressed. Recombinant PCR techniques were employed to produce a 5'-histidine tagged protein for use in future protein purification and reconstitution experiments. Site-directed mutagenesis was also applied to produce a protein in which the highly conserved arginine at position 304 was replaced by a glutamic acid residue (R304E). Factors influencing protein yield were investigated, the data obtained being used to optimise expression in Sf cells. Removal of the upstream untranslated sequence of the cDNA was found to increase the level of expression suggesting the presence of regulatory sequences in this region. Wild type and modified forms of CIC-1 were expressed at high levels in Sf cells, protein being easily visualised on coomassie-stained polyacrylamide gels.

Whole-cell patch-clamping was used directly on CIC-1-expressing Sf9 cells to assess the biophysical properties of the channel in this system. Current kinetics were investigated and found to be similar to those reported by others using heterologously expressed rat and human CIC-1 protein in other cell lines and were in keeping with those expected for the channel responsible for the large chloride flux in skeletal muscle. Distinctive features of whole-cell currents included deactivation at hyperpolarising potentials and rectification at positive potentials. Under the conditions used here, the deactivating current was found to be made up of three components, two exponentially decaying and one constant. The time constants of the two exponential components, designated fast and slow, were around 6 and 25ms (test potential -120mV) respectively. On a small number of occasions when longer lasting voltage pulses were employed, a third exponentially decaying component could be

extracted with a time constant of several hundred milliseconds (Astill et al., 1995a). No attempt has been made, at this stage, to characterise this component in any detail. In contrast, the two faster components were studied in detail and their time constants were found to be voltage dependent, the fast component becoming faster and the slow component slower as the test potential became less negative. Increases in total instantaneous and quasi-steady state currents along with a slowing of the deactivation process were also noted during the first 10 - 20 minutes of current recording.

The effects of various compounds known to interfere with chloride permeation in muscle and other tissues were also assessed. Anthracene-9-carboxylate was found to be the most potent blocker exhibiting an IC_{50} of around $20\mu M$. Most other compounds tested displayed potencies in the millimolar range with the exception of niflumate for which preliminary results indicated a potency in the $50 - 100\mu M$ range. Different compounds were found to alter channel behaviour in varying ways suggesting several, discrete sites of interaction with the channel protein. A number of compounds, including 2-(4-chlorophenoxy)-propionate (clofibric acid) and its enantiomers, induced changes in current kinetics remarkably similar to those observed by other investigators working with *in vitro* expressed ClC-1 incorporating mutations found in the human myotonic muscle disease dominant myotonia congenita (Thomsen's disease).

Results obtained with the point mutant produced in our laboratories (R304E), in particular its differing response to Zn^{++} at various external pHs, shed some doubt on the current proposed topological model of this protein and indicate the possible involvement of histidine residues in normal channel operation.